课题基金 / 基金详情

SECRETORY PHOSPHOLIPASE A2 IN ACUTE CHEST SYNDROME TRIAL

SECRETORY PHOSPHOLIPASE A2 IN ACUTE CHEST SYNDROME TRIAL
分泌性磷脂酶 A2 在急性胸部综合征试验中的应用
批准号：
6308646
负责人：
LORI A STYLES
金额：
$2.58万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6308646
关键词：
blood disorder diagnosis blood transfusion clinical research human subject human therapy evaluation medical complication patient care management phospholipase A2 sickle cell crisis

项目摘要

项目成果

LORI A STYLES的其他基金

相似基金

相关文献

中文摘要
翻译
急性胸综合征（ACS）是镰状细胞病患者住院治疗的第二大常见原因，也是导致患者死亡的主要原因。我们发现，通过分泌磷脂酶A1水平，我们可以预测哪些血管闭塞危像患者会发展为ACS。本研究的目的是：确定红细胞输注是否会消除或减轻ACS的严重程度；并比较输血干预与ACS标准管理的毒性。
英文摘要
Acute chest syndrome (ACS) is the second most common cause of hospitalizations and the leading cause of death in patients with sickle cell disease. We have found that using secretory phospholipase A1 levels, we can predict which patients with vaso-occlusive crisis will go on to develop ACS. The aims of this study are to: determine if red blood cell transfusion will eliminate or lessen the severity of ACS; and to compare the toxicity of the transfusion intervention wiht the standard management of ACS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Arginine as Prophylactic Therapy in Sickle Cell Disease
Arginine as Prophylactic Therapy in Sickle Cell Disease
Arginine as Prophylactic Therapy in Sickle Cell Disease
Arginine as Prophylactic Therapy in Sickle Cell Disease
海外基金